



CHEPLAPHARM CONTINUES ITS EXPANSION COURSE AND COMPLEMENTS ITS PORTFOLIO WITH FOUR FURTHER PRODUCTS

Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®, KONAKION®, LARIAM® and INHIBACE®/Plus from F. Hoffmann-La Roche Ltd. The amount of investment for the newly acquired products is in the lower three-digit million euros range. As a result, CHEPLAPHARM provides further job opportunities for 40 new employees.

This acquisition reflects once again our already well-established success strategy "Buy-And-Build". With the sustainable integration and active management of the products, we expect an additional turnover at year end in the middle double-digit million euros range, especially as KONAKION® and CYMEVENE® are in the market leader position in many countries.

"With target-oriented local marketing strategies and geographical expansion into selected countries, we want to make the two highly ethical and vital products CYMEVENE® and KONAKION® specifically accessible to patients", says the Management.

In the area of Cardiology, INHIBACE®/Plus perfectly complements CHEPLAPHARM's product portfolio together with the beta blocker DILATREND®, which was acquired in early 2017.

Based on our trustful and success-oriented cooperations with our worldwide distribution partners, we want to continue benefitting from and expanding the future potential of our newly acquired products. In this regard, CHEPLAPHARM particularly pays attention to low-revenue regions. The Made-In-Europe quality feature is a significant advantage in this context.

Due to the takeover of the products, the share of export increases from currently 93 percent to 96 percent. Thus, CHEPLAPHARM's country- and product mix is optimally diversified and the company continues with consistence its way to becoming an internationally operating "Specialty Pharma"-company.

Press Office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)